BR9713366A - Análogos de heptapeptìdeo oxitocina - Google Patents

Análogos de heptapeptìdeo oxitocina

Info

Publication number
BR9713366A
BR9713366A BR9713366-3A BR9713366A BR9713366A BR 9713366 A BR9713366 A BR 9713366A BR 9713366 A BR9713366 A BR 9713366A BR 9713366 A BR9713366 A BR 9713366A
Authority
BR
Brazil
Prior art keywords
analogs
oxytocin
synthesis
amino acid
heptapeptide
Prior art date
Application number
BR9713366-3A
Other languages
English (en)
Other versions
BR9713366B1 (pt
Inventor
Per Merlin
Anders Nilsson
Jerzy Trojnar
Carl-Johan Aurell
Pierre Riviere
Robert Haigh
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BR9713366A publication Critical patent/BR9713366A/pt
Publication of BR9713366B1 publication Critical patent/BR9713366B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"ANáLOGOS DE HEPTAPEPTìDEO OXITOCINA". Trata-se de análogos heptapeptídeos ou seus sais farmaceuticamente aceitáveis, que consistem em uma metade hexapeptídeo S e um resíduo beta-amino álcool terminal -C Z ligados à metade S por uma ligação amida, onde o beta-amino álcool Z é -NR-CH (Q) - CH~ 2~OH, Q é (CH~ 2~) -NH-A, n é 1-6 e A é H ou C-(=NH)NH~ 2~, é R é CH~ 3~ ou C~ 2~H~ 5~, e a metade S onde X é um alfa-aminoácido D-aromático e Y é um alfa-aminoácido alifático, e têm atividade antagonista oxitocina. Um processo de sua síntese; composições farmacêuticas contendo estes análogos; a síntese de tais composições; eum processo de controle de contrações uterinas, também são descritos.
BRPI9713366-3A 1996-11-26 1997-11-21 análogos de heptapeptìdeo oxitocina. BR9713366B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue
PCT/SE1997/001968 WO1998023636A1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues

Publications (2)

Publication Number Publication Date
BR9713366A true BR9713366A (pt) 2000-01-25
BR9713366B1 BR9713366B1 (pt) 2010-05-18

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9713366-3A BR9713366B1 (pt) 1996-11-26 1997-11-21 análogos de heptapeptìdeo oxitocina.

Country Status (35)

Country Link
US (1) US6143722A (pt)
EP (1) EP0938496B1 (pt)
JP (1) JP3405460B2 (pt)
KR (1) KR100463132B1 (pt)
CN (1) CN1129606C (pt)
AR (1) AR008531A1 (pt)
AT (1) ATE242264T1 (pt)
AU (1) AU713424B2 (pt)
BR (1) BR9713366B1 (pt)
CA (1) CA2272990C (pt)
CZ (1) CZ299532B6 (pt)
DE (1) DE69722651T2 (pt)
DK (1) DK0938496T3 (pt)
EE (1) EE03832B1 (pt)
ES (1) ES2203823T3 (pt)
HK (1) HK1022481A1 (pt)
HR (1) HRP970630B1 (pt)
HU (1) HU228568B1 (pt)
IL (1) IL129519A (pt)
LT (1) LT4650B (pt)
LV (1) LV12350B (pt)
MY (1) MY125555A (pt)
NO (1) NO321380B1 (pt)
NZ (1) NZ336445A (pt)
PL (1) PL189292B1 (pt)
PT (1) PT938496E (pt)
RO (1) RO120772B1 (pt)
RU (1) RU2180668C2 (pt)
SE (1) SE9604341D0 (pt)
SI (1) SI20026B (pt)
SK (1) SK283800B6 (pt)
TR (1) TR199901028T2 (pt)
UA (1) UA54459C2 (pt)
WO (1) WO1998023636A1 (pt)
ZA (1) ZA9710518B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
DE60309847T2 (de) * 2002-02-27 2007-10-18 Ferring B.V. Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
EP1504268A2 (en) * 2002-05-02 2005-02-09 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
EP1530967B1 (en) * 2003-11-13 2006-05-03 Ferring B.V. Blister pack and solid dosage form comprising desmopressin
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
KR101522747B1 (ko) 2007-08-06 2015-05-26 알레간 인코포레이티드 데스모프레신 약물 전달을 위한 방법 및 장치
NZ587817A (en) * 2008-03-31 2012-05-25 Ferring Bv Oxytocin analogues
LT2712622T (lt) 2008-05-21 2016-09-26 Ferring B.V. Burnoje disperguojamas desmopresinas, skirtas nikturijos netrikdomo miego pirminio periodo pailginimui
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
AU2011278038B2 (en) 2010-07-15 2017-02-02 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
ES2742299T3 (es) 2011-03-09 2020-02-13 Jitsubo Co Ltd Nuevos péptidos entrecruzados que contienen una estructura entrecruzada no peptídica, método para sintetizar péptidos entrecruzados y nuevo compuesto orgánico utilizado en el método
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
EP3037101B1 (en) 2014-12-22 2019-03-06 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
EP3359557A1 (en) 2015-10-06 2018-08-15 Ferring B.V. New methods for making barusiban and its intermediates
RS63286B1 (sr) 2016-01-04 2022-06-30 ObsEva SA Istovremeno davanje alfa-amino estra hidroksipropiltiazolidin karboksamidnog derivata i tokolitičkog agensa
MX2019000498A (es) 2016-07-21 2019-09-16 ObsEva SA Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos.
WO2021043726A1 (en) 2019-09-03 2021-03-11 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4103750A1 (en) 2020-02-10 2022-12-21 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036973A1 (en) * 1990-02-27 1991-08-28 Mark G. Bock Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE9500249L (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
NO992532D0 (no) 1999-05-26
LT4650B (lt) 2000-04-25
NO321380B1 (no) 2006-05-02
ZA9710518B (en) 1998-06-10
CZ183299A3 (cs) 2000-05-17
RO120772B1 (ro) 2006-07-28
ATE242264T1 (de) 2003-06-15
CZ299532B6 (cs) 2008-08-27
PT938496E (pt) 2003-10-31
AU5142998A (en) 1998-06-22
HU228568B1 (en) 2013-04-29
HUP0000577A3 (en) 2001-02-28
SK283800B6 (sk) 2004-02-03
BR9713366B1 (pt) 2010-05-18
CN1129606C (zh) 2003-12-03
HK1022481A1 (en) 2000-08-11
CN1238781A (zh) 1999-12-15
IL129519A0 (en) 2000-02-29
RU2180668C2 (ru) 2002-03-20
JP2000507617A (ja) 2000-06-20
DE69722651T2 (de) 2004-04-08
SI20026A (sl) 2000-02-29
EP0938496B1 (en) 2003-06-04
KR100463132B1 (ko) 2004-12-23
LV12350A (lv) 1999-09-20
NZ336445A (en) 2000-06-23
KR20000069045A (ko) 2000-11-25
EE9900210A (et) 1999-12-15
CA2272990A1 (en) 1998-06-04
AU713424B2 (en) 1999-12-02
ES2203823T3 (es) 2004-04-16
DE69722651D1 (en) 2003-07-10
PL189292B1 (pl) 2005-07-29
MY125555A (en) 2006-08-30
HUP0000577A2 (hu) 2000-11-28
DK0938496T3 (da) 2003-10-06
LV12350B (en) 1999-11-20
LT99052A (en) 2000-01-25
IL129519A (en) 2004-09-27
SE9604341D0 (sv) 1996-11-26
NO992532L (no) 1999-05-26
HRP970630A2 (en) 1998-10-31
UA54459C2 (uk) 2003-03-17
EP0938496A1 (en) 1999-09-01
SK70499A3 (en) 2000-10-09
AR008531A1 (es) 2000-01-19
TR199901028T2 (xx) 1999-07-21
JP3405460B2 (ja) 2003-05-12
HRP970630B1 (en) 2002-04-30
US6143722A (en) 2000-11-07
CA2272990C (en) 2002-11-19
WO1998023636A1 (en) 1998-06-04
EE03832B1 (et) 2002-08-15
SI20026B (sl) 2000-06-30

Similar Documents

Publication Publication Date Title
BR9713366A (pt) Análogos de heptapeptìdeo oxitocina
MX9801716A (es) Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
MY137301A (en) Peptide analogs as irreversible interleukin-1b protease inhibitors
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
CA2200192A1 (en) Amidino and Guanidino Substituted Inhibitors of Trypsin-Like Enzymes
HUP0100669A2 (hu) Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
ATE99698T1 (de) Peptide.
EP0215410A3 (en) Retro-inverso hexapeptide neurotensin analogs, process for their preparation and pharmaceutical compositions containing them
DE69723728D1 (de) Totalsynthese des amino hip analogen von didemnin a
DK164326C (da) 6,6-ethylen-15,16-methylen-3-oxo-17alfa-pregn-4-en-21,17-carbolactoner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater indeholdende dem
ES2001863A6 (es) Procedimiento para la fabricacion de derivados aminoalcoholes peptidicos que contienen un atomo de carbono tetrasubstituido, inhibidores de la renina y de las proteasas acidas
ES2012720A6 (es) Procedimiento para la obtencion de sales de adicion de acido de taurina o glicina amidada.
HUT53664A (en) Process for producing enzyme inhibiting amino acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
ES8206457A1 (es) Un procedimiento para la preparacion de compuestos n-acil-n- (cicloalquil) aminoacidos.
MC2254A1 (fr) Derives de la vasotocine
DE3666223D1 (en) Anticonvulsant agents
ATE46347T1 (de) Immunostimulierende peptide.
DE3476666D1 (en) Novel peptide, process for the preparation thereof and pharmaceutical composition containing said peptide
DE3855751D1 (en) Hypoglycemische peptide
CA2123890A1 (en) Novel Sulfonic Acid Derivative and Medicinal Use Thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/05/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 16A, 17A E 18A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.